RE:RE:RE:Random thought on debt paydown...
Yes I know, the EBITDA problem is making analysts job very difficult. This why prices are all over the place. There is also the issue of future drug pricing. That being said, CXR has plenty of cash and will use that to take care of near term liabilities.
The UK gov is having another reading of the Health Service Medical Supplies Bill on Monday. Perhaps this will give us an idea of CRX's future prospects in the UK.
https://services.parliament.uk/bills/2016-17/healthservicemedicalsuppliescosts.html